🇺🇸 FDA
Pipeline program

REGN7999

R7999-BThal-2350

Phase 2 small_molecule active

Quick answer

REGN7999 for Non-Transfusion Dependent Beta-Thalassemia (NTDT) is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials